ABSTRACT
Objective: assessment of the efficacy and safety of the use of anticoagulant, glucocorticosteroid, metabolic therapy in patients with COVID-19 at the inpatient stage of treatment. Material and methods. In February 2021, a prospective, randomized, single-center, continuous comparative study was organized on the basis of the Gomel City Clinical Hospital No. 3, which included 827 patients with moderate and severe clinical course of COVID-19. Results. Stratification of the risks of an unfavorable outcome in patients with moderate and severe clinical course of COVID-19 made it possible to optimize treatment, with the selection of optimal doses of anticoagulant and glucocorticosteroid therapy, which led to an increase in patient survival. A high level of blood lactate reflects the degree of damage to the lung tissue, the severity of the course of the disease and requires an increase in the dose of anticoagulant therapy. The use of thiotriazoline effectively reduces the level of lactate, which makes it possible to restore the energy balance of the cell. Conclusion. The use of therapeutic (intermediate) doses of anticoagulant and optimal glucorticosteroid therapy in patients at high risk of poor outcomes with moderate and severe clinical course of COVID-19, can increase the survival rate from 82.1 to 96.8%, p<0.0001. The appointment of anticoagulant therapy was complicated by "minor" bleeding in 2.13% in the main group, in 2.11% in the control group, p>0.05, and the use of glucocorticosteroids was complicated by newly diagnosed diabetes mellitus (2.13% in the main group, 1.81% in the control group, p>0.05), which allows us to consider the therapy used is safe. The use of the metabolic, antioxidant agent thiotriazoline in patients with an LDH level of more than 800 U/L and with a high risk of an unfavorable outcome led to a decrease in LDH within five days of treatment by 447.9 U/L in the main group compared with the control group by 124.0 U/L (p=0.0001), which was accompanied by an improvement in the general condition, increased physical activity, and an earlier start of rehabilitation.Copyright © 2022 by the authors.
ABSTRACT
Relevance. Many countries around the world are developing effective vaccines against SARS-CoV-2. The measure of the effectiveness of the vaccination process has traditionally been antibody production. The frequency and intensity of adverse reactions is also an important factor in making a decision regarding a vaccine. This study presents the results of the evaluation of the formation of humoral immunity and the occurrence of reactions in response to the administration of Sputnik V (Gam-COVID-Vac), RF, and Sinopharm (BBIBP-CorV), PRC. Aim. Analyze immunogenicity and reactogenicity of COVID-19 vaccines used in the Republic of Belarus (Sputnik V and Sinopharm). Materials and methods. Evaluation of postvaccination immune response by enzyme immunoassay and differential enzyme immunoassay for class G immunoglobulins to S-and N-proteins SARS-CoV-2. Blood plasma of the study participants was used as biological material. Blood sampling was performed 3 times: immediately before the first vaccine dose, on day 42, and 6 months after the first vaccine dose. To evaluate the frequency and intensity of postvaccination reactions, study participants were questioned. Results. At 42 days after administration of both vaccines, antibody levels are rising, with a significantly higher quantitative IgG count for the Sputnik V vaccine. This trend is also observed 6 months after the first dose of both vaccines, both among those previously infected with SARS-CoV-2 and those without a history of COVID-19. The comparison of Sputnik V and Sinopharm vaccine groups in terms of IgG (BAU/ml) levels to S-and N-proteins revealed a statistically significant difference in IgG levels to S-protein: the Sputnik V vaccine group had significantly higher IgG levels to S-protein than the Sinopharm vaccine group (p = 0.0000196). The incidence of adverse reactions in this study was 45%. All reactions noted were mild to moderate in severity. The most common were soreness and redness at the injection site, elevated body temperature, and a combination of several reactions. The increased body temperature after vaccination was more common among those vaccinated with the Sputnik V vaccine. Conclusion. Compared to Sinopharm, Sputnik V vaccine produces higher antibody level. Adverse reactions were observed in both vaccinated groups. However, significant statistical differences were found with regard to fever in the Sputnik V vaccine group, which occurred more frequently. © 2023, Numikom. All rights reserved.
ABSTRACT
Objective: to assess the efficacy of COVID-19 vaccination against in organized, group. Material(s) and Method(s): A total of 122 adults, employees of a higher education institution participated, in the study. Study participants were observed, prospectively and. filled, out a questionnaire where they indicated their age, presence of chronic diseases, history of COVID-19 and. vaccination, status. Finding(s): the study participants were divided, into two groups: 59 vaccinated. (48.36%) and. 63 unvaccinated. (51.64%) individuals with no differences in age between the groups. There were significantly fewer confirmed, cases of COVID-19 in the vaccinated, group (p=0,0008457, df=1;chi2=11,138), significant differences (p=0.0084;df=4;chi2=13.678) were observed, in the number of cases among study participants based, on their vaccination, status. Conclusion(s): participants diagnosed, with pneumonia were 75% unvaccinated. (p=0,00729;df=1;chi2=7,2). AH hospitalized. study participants were unvaccinated. (p=0,004678;chi2=8,0). None of the vaccinated, participants needed, respiratory support (p=0,0455;df=1;chi2=4,0). Chronic disease in vaccinated, subjects made a significant (p=0,04563;df=2;chi2=6,1743) impact on COVID-19 severity.Copyright © 2022 Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR). All rights reserved.
ABSTRACT
Objective: to assess the efficacy of COVID-19 vaccination against in organized, group. Material(s) and Method(s): A total of 122 adults, employees of a higher education institution participated, in the study. Study participants were observed, prospectively and. filled, out a questionnaire where they indicated their age, presence of chronic diseases, history of COVID-19 and. vaccination, status. Finding(s): the study participants were divided, into two groups: 59 vaccinated. (48.36%) and. 63 unvaccinated. (51.64%) individuals with no differences in age between the groups. There were significantly fewer confirmed, cases of COVID-19 in the vaccinated, group (p=0,0008457, df=1;chi2=11,138), significant differences (p=0.0084;df=4;chi2=13.678) were observed, in the number of cases among study participants based, on their vaccination, status. Conclusion(s): participants diagnosed, with pneumonia were 75% unvaccinated. (p=0,00729;df=1;chi2=7,2). AH hospitalized. study participants were unvaccinated. (p=0,004678;chi2=8,0). None of the vaccinated, participants needed, respiratory support (p=0,0455;df=1;chi2=4,0). Chronic disease in vaccinated, subjects made a significant (p=0,04563;df=2;chi2=6,1743) impact on COVID-19 severity.Copyright © 2022 Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR). All rights reserved.
ABSTRACT
Objective: to assess the efficacy of COVID-19 vaccination against in organized, group. Materials and methods: A total of 122 adults, employees of a higher education institution participated, in the study. Study participants were observed, prospectively and. filled, out a questionnaire where they indicated their age, presence of chronic diseases, history of COVID-19 and. vaccination, status. Findings: the study participants were divided, into two groups: 59 vaccinated. (48.36%) and. 63 unvaccinated. (51.64%) individuals with no differences in age between the groups. There were significantly fewer confirmed, cases of COVID-19 in the vaccinated, group (р=0,0008457, df=1;χ2=11,138), significant differences (p=0.0084;df=4;χ2=13.678) were observed, in the number of cases among study participants based, on their vaccination, status. Conclusion: participants diagnosed, with pneumonia were 75% unvaccinated. (p=0,00729;df=1;χ2=7,2). AH hospitalized. study participants were unvaccinated. (p=0,004678;χ2=8,0). None of the vaccinated, participants needed, respiratory support (p=0,0455;df=1;χ2=4,0). Chronic disease in vaccinated, subjects made a significant (p=0,04563;df=2;χ2=6,1743) impact on COVID-19 severity. © 2022 Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR). All rights reserved.
ABSTRACT
Objective: to assess the efficacy of COVID-19 vaccination against in organized, group. Material(s) and Method(s): A total of 122 adults, employees of a higher education institution participated, in the study. Study participants were observed, prospectively and. filled, out a questionnaire where they indicated their age, presence of chronic diseases, history of COVID-19 and. vaccination, status. Finding(s): the study participants were divided, into two groups: 59 vaccinated. (48.36%) and. 63 unvaccinated. (51.64%) individuals with no differences in age between the groups. There were significantly fewer confirmed, cases of COVID-19 in the vaccinated, group (p=0,0008457, df=1;chi2=11,138), significant differences (p=0.0084;df=4;chi2=13.678) were observed, in the number of cases among study participants based, on their vaccination, status. Conclusion(s): participants diagnosed, with pneumonia were 75% unvaccinated. (p=0,00729;df=1;chi2=7,2). AH hospitalized. study participants were unvaccinated. (p=0,004678;chi2=8,0). None of the vaccinated, participants needed, respiratory support (p=0,0455;df=1;chi2=4,0). Chronic disease in vaccinated, subjects made a significant (p=0,04563;df=2;chi2=6,1743) impact on COVID-19 severity.Copyright © 2022 Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR). All rights reserved.
ABSTRACT
Relevance. The first case of COVID-19 was registered in 2019. Several months later, the local outbreak became pandemic. The only way to curb the spread of SARS-CoV-2 infection is mass vaccination that aims to form a herd immunity. The success of vaccination depends on people’s acceptance, which might be problematic. The review summarizes the main barriers to mass vaccination against COVID-19, categorizing people based on their willingness to vaccinate, and pointing out possible areas of work to overcome the barriers listed above. Aim. Analyze the problem of mass rejection of vaccination against COVID-19. Determine possible solutions. Conclusion. The main reason for refusal to vaccinate against COVID-19 is the lack of public awareness about the safety and efficacy of vaccines. This review lists possible approaches to creating a supportive information environment and ways to stimulate citizens to accelerate the rates of mass vaccination. © 2022, Numikom. All rights reserved.
ABSTRACT
Objective. To estimate efficiency and safety of remdesivir in treating new coronavirus infection in pregnant. Materials and methods. A retrospective cohort study including 61 medical patient’s records who underwent COVID-19 and being pregnant more than 20 weeks was conducted. Medical case histories were divided into 2 groups: the main one with the use of remdesivir treatment (n = 35) and control one (n = 26) without it. The groups were representative by age, anthropometric data and comorbidity (p > 0.05). Results. The use of remdesivir in pregnant patients with COVID-19 causes a reduction in fever by 15% and achievement of target saturation values in 94.3% of cases, reduces С-reaction protein (CRP) levels by 3.5 times, D-dimer by 2.6, Lactat Dehydrogenase (LDG) by 1.4 times on 5th day from the moment of hospitalization, reduces its duration by 30.8%, does not affect the course of pregnancy and the frequency of Cesarean section. Conclusion. The use of remdesivir in the treatment of COVID-19 in pregnant patients with a gestation period of more than 20 weeks is effective, as evidenced by the shortening of the fever period, the duration of hospitalization, improving oxygenation, reduction of laboratory markers "cytokine storm" in blood levels and safe due to the lack of impact on pregnancy and delivery strategy.
ABSTRACT
Objective: assessment of the efficacy and safety of the use of anticoagulant, glucocorticosteroid, metabolic therapy in patients with COVID-19 at the inpatient stage of treatment. Material and methods. In February 2021, a prospective, randomized, single-center, continuous comparative study was organized on the basis of the Gomel City Clinical Hospital No. 3, which included 827 patients with moderate and severe clinical course of COVID-19. Results. Stratification of the risks of an unfavorable outcome in patients with moderate and severe clinical course of COVID-19 made it possible to optimize treatment, with the selection of optimal doses of anticoagulant and glucocorticosteroid therapy, which led to an increase in patient survival. A high level of blood lactate reflects the degree of damage to the lung tissue, the severity of the course of the disease and requires an increase in the dose of anticoagulant therapy. The use of thiotriazoline effectively reduces the level of lactate, which makes it possible to restore the energy balance of the cell. Conclusion. The use of therapeutic (intermediate) doses of anticoagulant and optimal glucorticosteroid therapy in patients at high risk of poor outcomes with moderate and severe clinical course of COVID-19, can increase the survival rate from 82.1 to 96.8%, p<0.0001. The appointment of anticoagulant therapy was complicated by “minor” bleeding in 2.13% in the main group, in 2.11% in the control group, p>0.05, and the use of glucocorticosteroids was complicated by newly diagnosed diabetes mellitus (2.13% in the main group, 1.81% in the control group, p>0.05), which allows us to consider the therapy used is safe. The use of the metabolic, antioxidant agent thiotriazoline in patients with an LDH level of more than 800 U/L and with a high risk of an unfavorable outcome led to a decrease in LDH within five days of treatment by 447.9 U/L in the main group compared with the control group by 124.0 U/L (p=0.0001), which was accompanied by an improvement in the general condition, increased physical activity, and an earlier start of rehabilitation. © 2022 by the authors.
ABSTRACT
The COVID-19 pandemic has been going on for more than a year and a half, and the number of confirmed cases of infection in the world has already exceeded 150 million people. The multisystemic nature of the lesions in COVID-19, as well as the Post-COVID-19 syndrome, has been proven, which requires a rethinking of the rehabilitation of such patients. This lecture discusses current approaches to medical rehabilitation in patients with COVID-19 from the view of an infectious disease specialist and a pulmonologist. Methods and exercises of respiratory rehabilitation, including early ones, are indicated in detail. The directions of pharmacological and dietary support of rehabilitation, as well as vaccination after COVID-19 in the aspect of rehabilitation are presented. The directions of studying the human respiratory microbiome in the context of rehabilitation after COVID-19 are proposed. © 2021,HIV Infection and Immunosuppressive Disorders. All Rights Reserved.